Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury-Reference-Cited by-同舟云学术

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury

Published:2022-03-16 Issue:3 Volume:5 Page:e222735
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Puskarich Michael A.¹²,Ingraham Nicholas E.³,Merck Lisa H.⁴,Driver Brian E.²,Wacker David A.³,Black Lauren Page⁵,Jones Alan E.⁶,Fletcher Courtney V.⁷,South Andrew M.⁸⁹¹⁰,Murray Thomas A.¹¹,Lewandowski Christopher¹²,Farhat Joseph¹³,Benoit Justin L.¹⁴,Biros Michelle H.¹,Cherabuddi Kartik⁴,Chipman Jeffrey G.¹⁵,Schacker Timothy W.¹⁶,Guirgis Faheem W.⁵,Voelker Helen T.¹¹,Koopmeiners Joseph S.¹¹,Tignanelli Christopher J.¹⁵,Nelson Andrew C¹⁷,Hall Alex¹⁷,Wright David¹⁷,Reilkoff Ronald A¹⁷,Bold Tyler¹⁷,Beckman Kenneth¹⁷,Langlois Ryan¹⁷,Aliota Matthew T¹⁷,Galbriath James¹⁷,Beyer Margaret¹⁷,Salmen Chas¹⁷,Byrne Dana¹⁷,Roberts Brian¹⁷,James Nastasia¹⁷,

Affiliation:

1. Department of Emergency Medicine, University of Minnesota, Minneapolis

2. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota

3. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis

4. Department of Emergency Medicine, University of Florida College of Medicine, Gainesville

5. Department of Emergency Medicine, University of Florida College of Medicine, Jacksonville

6. Department of Emergency Medicine, University of Mississippi Medical Center, Jackson

7. Center for Drug Discovery, University of Nebraska Medical Center, Omaha

8. Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children's Hospital, Winston Salem, North Carolina

9. Division of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston Salem, North Carolina

10. Department of Surgery-Hypertension and Vascular Research, Wake Forest School of Medicine, Winston Salem, North Carolina

11. Department of Biostatistics, School of Public Health, University of Minnesota, Minneapolis

12. Department of Emergency Medicine, Henry Ford Hospital, Wayne State University, Detroit, Michigan

13. Department of Surgery, North Memorial Medical Center, Minneapolis, Minnesota

14. Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio

15. Department of Surgery, University of Minnesota, Minneapolis

16. Division of Infectious Disease, Department of Medicine, University of Minnesota, Minneapolis

17. for the Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2790162/puskarich_2022_oi_220109_1652198565.7699.pdf

Reference40 articles.

1. Understanding the renin-angiotensin-aldosterone–SARS-CoV axis: a comprehensive review.;Ingraham;Eur Respir J,2020

2. Immunomodulation in COVID-19.;Ingraham;Lancet Respir Med,2020

3. COVID-19, ACE2, and the cardiovascular consequences.;South;Am J Physiol Heart Circ Physiol,2020

4. Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients.;Osman;Front Immunol,2021

5. A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure.;Files;Am J Physiol Lung Cell Mol Physiol,2021

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock;Annals of Intensive Care;2023-12-16

2. Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies;Scientific Reports;2023-11-20

3. Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers;Metabolites;2023-10-24

4. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials;European Heart Journal - Cardiovascular Pharmacotherapy;2023-09-22

5. Reply to: RAAS inhibitors in COVID-19: Not all are created equal!;Revista Portuguesa de Cardiologia;2023-09